Dosing & Uses
Dosage Forms & Strengths
Integrase strand transfer inhibitor (INSTI) indicated in combination with other ARTs for treatment of HIV-1 infection
Treatment-naïve or treatment-experienced INSTI-naïve: 50 mg PO qDay
INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50 mg PO BID
Treatment-naïve or treatment-experienced INSTI-naïve when coadministration with potent UGT1A/CYP3A inducers (eg, efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, rifampin): Increase dose to 50 mg PO BID
Mild-to-moderate hepatic impairment (Child-Pugh A or B): No dosage adjustment required
Severe hepatic impairment (Child-Pugh C): Not recommended
- Plasma concentrations were decreased in subjects with severe renal impairment
- No dosage adjustment required for treatment-naïve or treatment-experienced and INSTI-naïve patients with mild, moderate, or severe renal impairment or for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance) with mild or moderate renal impairment
- Severe renal impairment in for INSTI-experienced patients with resistance: Not recommended; decrease in dolutegravir concentrations may result in loss of therapeutic effect and development of resistance
Poor virologic response was observed in subjects treated with TIVICAY 50 mg BID with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions, including L74I/M, E138A/D/K/T, G140A/S, Y143H/R, E157Q, G163E/K/Q/R/S, or G193E/R
In patients with underlying hepatitis B or C, measure hepatic enzymes before initiating therapy and periodically thereafter
Dosage Forms & Strengths
Indicated in combination with other ARTs for treatment-naïve or treatment-experienced INSTI-naïve children weighing at least 30 kg
<30 kg: Safety and efficacy not established
≥30 kg to <40 kg: 35 mg PO qDay (ie, one 25-mg tablet and one 10-mg tablet)
≥40 kg: 50 mg PO qDay
Treatment-naïve or treatment-experienced INSTI-naïve when coadministration with potent UGT1A/CYP3A inducers (eg, efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, rifampin): Increase weight-based dose to twice daily
Safety and efficacy have not been established in pediatric patients weighing <30 kg or in pediatric patients who are INSTI-experienced with documented or clinically suspected resistance to other INSTIs (ie, raltegravir, elvitegravir)
Serious - Use Alternative
Significant - Monitor Closely
Increased cholesterol and triglycerides (up to 17%)
Increased lipase (1-8%)
Increased creatinine kinase (3-4%)
Increased AST (2-3%)
Increased ALT (2%)
Increased bilirubin (<1-2%)
GI disorders (<2%)
Renal impairment (<2%)
Coadministration with dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events
Hypersensitivity reactions reported; characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury
Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations
Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” observed
Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy; may develop an inflammatory response to indolent or residual opportunistic infections (eg, Mycobacterium avium infection, cytomegalovirus, Pneumocystis jiroveci pneumonia [PCP], or tuberculosis) or autoimmune disorders (eg, Graves’ disease, polymyositis, and Guillain-Barre’ syndrome)
Inducers of UGT1A1 and CYP3A (eg, oxcarbazepine, phenytoin, phenobarbital, carbamazepine, St John’s wort, rifampin) decrease dolutegravir
Coadministration with medications containing polyvalent cations decrease dolutegravir systemic exposure; give dolutegravir 2 hr before or 6 hr after polyvalent cations (eg, antacids, laxatives, sucralfate, iron supplements, calcium supplements, buffered medications)
Pregnancy & Lactation
Pregnancy Category: B
Antiretroviral pregnancy registry: 1-800-258-4263
Lactation: Unknown if distributed in human breast milk
The CDC recommends that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Integrase strand transfer inhibitor (INSTI); inhibits catalytic activity of HIV-1 integrase, an HIV encoded enzyme required for viral replication
Peak plasma time: 2-3 hr
Peak plasma concentration: 3.67-4.15 mcg/mL
AUC 53.6-75.1 mcg•h/mL
Protein bound: ≥98.9%
Vd: 17.4 L; 4-232 ng/mL (CSF)
Metabolized by UGT1A1 with some contribution from CYP3A
Half-life: 14 hr
Clearance: 1 L/hr
Excretion: 53% feces (unchanged); 31% urine (as ether glucuronide, benzylic carbon, or N-dealkylation product); <1% urine (unchanged)
May take with or without food
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.